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Treatment of Type 2 diabetes with glucagon‐like peptide (GLP)‐1 receptor agonists leads to a modest increase in fasting plasma pancreatic enzyme levels, i.e. lipase and amylase [1](#dme13160-bib-0001){ref-type="ref"}, [2](#dme13160-bib-0002){ref-type="ref"}. The relevance of this observation is currently unknown, although GLP‐1 receptor agonists have been linked to the development of pancreatitis [1](#dme13160-bib-0001){ref-type="ref"}. The rate by which these enzymes increase remains largely unstudied. To date, the earliest observed enzyme increment is 4 weeks after drug initiation, while elevated levels are sustained during prolonged treatment [1](#dme13160-bib-0001){ref-type="ref"}, [2](#dme13160-bib-0002){ref-type="ref"}. *In vitro,* native GLP‐1 increases amylase secretion from isolated pancreatic acinar cells within 30 min [3](#dme13160-bib-0003){ref-type="ref"}, suggesting that the effect is immediate; however, in a recent study by Sonne *et al*. [4](#dme13160-bib-0004){ref-type="ref"}, liquid meal‐stimulated endogenous GLP‐1 (reaching two to three times fasting GLP‐1 levels) did not raise plasma lipase or amylase levels in people with Type 2 diabetes within 4 h. Whether plasma concentrations of therapeutic GLP‐1 receptor agonist increase pancreatic enzyme levels acutely in the clinical setting remains unclear. In the present study, we measured plasma lipase and amylase during i.v. administration of the GLP‐1 receptor agonist exenatide in people with Type 2 diabetes.

A detailed description of the design of this double‐blind, placebo‐controlled trial has been reported previously [5](#dme13160-bib-0005){ref-type="ref"}. Briefly, 57 people with Type 2 diabetes (mean ± [sd]{.smallcaps} age 62.8 ± 6.9 years, BMI 31.8 ± 4.1 kg/m^2^, HbA~1c~ 56 ± 7 mmol/mol (7.3 ± 0.6%), diabetes duration 7.8 ± 4.9 years) were randomized to exenatide (AstraZeneca, London, UK) or placebo (isotonic saline). Exenatide was administered i.v., with a loading dose of 50 ng/min in 30 min, followed by continuous infusion of 25 ng/min, which is known to achieve steady‐state plasma concentrations within the therapeutically relevant range (130--150 pg/ml) [6](#dme13160-bib-0006){ref-type="ref"}. Plasma lipase and amylase were measured at baseline (\~150 min before the start of intervention), and repeatedly during intervention in both the fasting state and after a high‐fat mixed meal (905.7 kCal; 50 g fat, 36.8 g protein and 75 g carbohydrates), using enzymatic colorimetric assays (Modular Analytics; Roche Diagnostics GmbH, Mannheim, Germany). Statistical analyses were performed using linear mixed models, which inherently correct for the multiple time points tested.

Lipase and amylase levels were in the normal range at baseline (mean ± [sem]{.smallcaps} lipase 44.6 ± 3.3 U/l and amylase 50.7 ± 2.4 U/l) and showed a similar initial decrease in both intervention groups (between‐group difference *P *\>* *0.05; Fig. [1](#dme13160-fig-0001){ref-type="fig"}). Thereafter, plasma amylase levels showed an increase during exenatide infusion, but not during placebo infusion. After 280 min infusion, amylase was significantly higher with exenatide compared with placebo (4.7 ± 1.4 U/l; *P *=* *0.001). Amylase levels in individual participants did not exceed 3 × the upper limit of normal (maximum value was 110 U/l). Neither exenatide nor placebo had an effect on plasma lipase levels.

![Pre‐ and postprandial effects of exenatide (circles, red solid line) and placebo (squares, black dashed line) on changes in plasma lipase and amylase concentrations. The high‐fat mixed meal was given 155 min after start of intervention. Asterisk indicates a statistically significant difference (*P *\<* *0.05) between the treatment groups at that time point.](DME-34-591-g001){#dme13160-fig-0001}

We show for the first time that the GLP‐1 receptor agonist exenatide increases amylase levels within hours after treatment initiation. The exact mechanisms by which exenatide increased amylase cannot be concluded from the present study; however, increased plasma pancreatic enzyme levels can be caused by acinar secretion or leakage. Because *in vitro* data show that GLP‐1 induces amylase secretion [3](#dme13160-bib-0003){ref-type="ref"}, it is likely that the increase in amylase in the present study was caused by augmented secretion. Also, in case of acute cellular damage with exenatide‐infusion, a combined increase in amylase and lipase would be expected [7](#dme13160-bib-0007){ref-type="ref"}, arguing against damage in the present study.

An initial decrease in both lipase and amylase levels was observed. This could be explained by circadian rhythm, because the baseline measurement and the first intervention measurement were separated by 3 h. Intraday variability has been shown in a canine study [8](#dme13160-bib-0008){ref-type="ref"}, and importantly, is not affected by feeding status. The fact that meal ingestion, and release of endogenous GLP‐1, has no effect on pancreatic plasma enzymes underlines our findings and those of Sonne *et al*. [4](#dme13160-bib-0004){ref-type="ref"}. However, the exenatide‐induced increase in amylase occurred after the test meal. Whether this increase would have occurred without a test‐meal remains speculative, although levels tended to rise before meal ingestion. Further studies are needed to determine the clinical relevance of these modest pancreatic enzyme elevations, and whether these increases are modulated by food intake.
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